Loss of Homeostatic Microglia Signature in Prion Diseases
Open accessThe DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index; 49 of the 115 sources its claims cite were checked for support.
Abstract
Prion diseases are neurodegenerative diseases that affect humans and animals. They are always fatal and, to date, no treatment exists. The hallmark of prion disease pathophysiology is the misfolding of an endogenous protein, the cellular prion protein (PrPC), into its disease-associated isoform PrPSc. Besides the aggregation and deposition of misfolded PrPSc, prion diseases are characterized by spongiform lesions and the activation of astrocytes and microglia. Microglia are the innate immune cells of the brain. Activated microglia and astrocytes represent a common pathological feature in neurodegenerative disorders. The role of activated microglia has already been studied in prion disease mouse models; however, it is still not fully clear how they contribute to disease progression. Moreover, the role of microglia in human prion diseases has not been thoroughly investigated thus far, and specific molecular pathways are still undetermined. Here, we review the current knowledge on the different roles of microglia in prion pathophysiology. We discuss microglia markers that are also dysregulated in other neurodegenerative diseases including microglia homeostasis markers. Data on murine and human brain tissues show that microglia are highly dysregulated in prion diseases. We highlight here that the loss of homeostatic markers may especially stand out.
Overview
CoChat Summary
TL;DR
This review argues that microglia are highly dysregulated in prion diseases, with a striking loss of homeostatic markers such as TMEM119 and P2RY12, especially in the thalamus, alongside activation and proliferation. It proposes a time-dependent dual role: early microglial activation may help clear PrPSc, whereas prolonged proinflammatory signaling and increased proliferation at later stages are harmful.
Key findings
- In murine prion disease, reactive microglia appear before symptoms, around day 70–80 in a region-dependent manner, mainly in the thalamus; terminal disease shows bushy/amoeboid morphology and significantly increased microglia numbers, highest in the thalamus.
- Homeostatic microglia proteins TMEM119 and P2RY12 are significantly reduced in terminal prion disease; the signature is still abundant in hippocampus but almost completely lost in thalamus, especially for P2RY12.
- In human sCJD, TMEM119 protein is significantly reduced, and the loss of this homeostatic marker appears more severe than in AD; CD68 is increased in sCJD frontal cortex compared with AD.
- Microglia may have a dual role: suppressing microglia proliferation in the clinical phase prolonged survival in mice, while partial depletion early enhanced prion accumulation and accelerated disease; complete depletion accelerated disease without enhanced PrPSc accumulation.
- RML mouse model timing: incubation to terminal disease about 150 days ± 5 days; infectious prions detectable around 30 dpi, PrPSc by Western blot after about 60 dpi, symptoms around day 90. sCJD incidence is 1–2 per million people per year.
Methods
- Narrative review of current knowledge on microglia in prion pathophysiology, including murine prion models and human sCJD.
- The authors present staining examples of different microglial markers in prion mouse models and human sCJD, and synthesize findings from cited transcriptomic, immunohistochemical, and functional studies.
- Main analysis is qualitative integration of data across prion strains (e.g., RML, 22L, ME7), brain regions, disease stages, and human tissues; no new systematic meta-analysis is reported.
Limitations
- Stated: the role of microglia in human prion diseases has not been thoroughly investigated, specific molecular pathways remain undetermined, and it is still unclear whether microglia contribute mainly through gain of detrimental functions, loss of protective homeostatic support, or both.
- Stated: discrepancies between P2ry12 RNA expression and protein loss remain unresolved; further experiments including mass spectrometry at different disease stages are needed, and larger patient sets are warranted for sCJD/AD comparisons.
- Stated: the transmissible nature and biosafety issues of prion disorders limit use of single-cell/nuclear sequencing in human prion disease. Evident: as a review, conclusions rely on heterogeneous cited models, stages, and regions rather than a systematic primary dataset.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Prion disease course in the mouse model. Prion diseases are neurodegenerative diseases that can be easily experimentally transmitted by the inoculation of mouse-adapted prions (such as the Rocky Mountain Laboratory strain; RML inoculum) to the brains of mice. Disease onset and clinical course are relatively accurately predictable, eventually leading to terminal disease usually within 150 ± 5 days after high-dose intracerebral inoculation. RML 5.0 is a specific and very well-characterized passage of RML that was and is used in several laboratories [35]. After a latency period, in this model, prion infectivity is already detectable in the brain at 30 days post infection (dpi), and misfolded PrPSc can be detected by Western blot (WB) at around 60 dpi. Symptoms appear around 90–100 dpi. Lower panel: The pan-microglia/monocyte marker ionized calcium-binding adaptor molecule 1 (IBA1) is shown at 80 dpi in different brain regions in comparison to the brain of a mock-infected control mouse (healthy brain). Note the region-specific change towards a reactive microglia phenotype in the thalamus in prion disease during the preclinical stage before the onset of symptoms, including an increase in microglia numbers [45,46,47]. Scale bar: 100 µm.](https://figures.cochat.ai/paper-figures/18195bd71ff649cfa86eb0dd5fb0b8d1/loss-of-homeostatic-microglia-signature-in-prion-diseases-figure-2.jpg)
![Figure 3 Microglia are highly activated in terminal prion disease. The pan-microglia/macrophage marker IBA1 is shown in mouse brain sections of (A) mock-infected healthy mice and (B) RML 5.0 prion-infected mice at a terminal disease state. (A) Microglia in the healthy brain show a ramified phenotype with a small soma and thin processes in all four regions displayed here (see magnified close-up). (B) During the terminal prion disease stage, microglia massively proliferate (see overview) and change their morphology towards bigger cell bodies and thicker arms (see close-ups) with a bushy appearance in the hippocampus and an amoeboid phenotype in the thalamus [45,46,47]. Scale bar: 100 µm; close-up: 50 µm.](https://figures.cochat.ai/paper-figures/cf42988cdc394ef095bffbd6b6179cce/loss-of-homeostatic-microglia-signature-in-prion-diseases-figure-3.jpg)
![Figure 4 Loss of microglial homeostatic phenotype in terminal prion disease. The microglia-specific homeostasis markers P2RY12 and TMEM119 show a ramified morphology of microglia in the healthy brain [47,73,97]. In terminal prion disease, this homeostatic microglia signature is lost in a region-dependent manner [47,73,97]. While the activated microglia in the dentate gyrus of the hippocampus display a bushy morphology with thick and retracted processes and still express both markers, microglia in the thalamus (posterior complex) have almost completely lost the expression of the markers, especially P2RY12. In the RML-prion mouse model, the deposition of PrPSc-specific staining is stronger in the thalamus than in the hippocampus in terminal prion disease. Scale bar: 25 µm.](https://figures.cochat.ai/paper-figures/af1240828f1d4c978289d35a831aaa6e/loss-of-homeostatic-microglia-signature-in-prion-diseases-figure-4.jpg)
![Figure 5 Loss of microglia homeostatic phenotype and increase in gliosis upon terminal prion disease. (A) IBA1 (green) and TMEM119 (red) co-localize in the hippocampus and thalamus in the healthy mouse brain, highlighting the ramified morphology with fine processes mainly stained by TMEM119 [47,73,97]. TMEM119 is highly reduced (white arrowhead) in the dentate gyrus of the hippocampus, and completely lost (white arrowhead) in the thalamus (posterior complex) in terminal prion disease [73]. Scale bar: 20 µm. (B) IBA1 (microglia/green) and GFAP (astrocytes/red) show intense dysregulation and are in close proximity (white asterisks) in the healthy brain and in terminal prion disease. (DAPI/nucleus in blue) [73]. Scale bar: 20 µm.](https://figures.cochat.ai/paper-figures/908390a5992a46dba8559929d7b9507e/loss-of-homeostatic-microglia-signature-in-prion-diseases-figure-5.jpg)
![Figure 6 Glia cells are highly dysregulated in human sCJD. Human brain tissues are usually fixed in 4% buffered formalin. To inactivate prion infectivity, tissues should be incubated in 98% formic acid for 1.5 h. Tissues from healthy human controls should be similarly treated with formic acid, to enable identical staining conditions. Frontal cortex and cerebellum brain sections from sCJD patients and control patients without neurologic disease are shown for (A) the pan-microglia/macrophage marker IBA1 and homeostatic microglia marker TMEM119 [97]. Note that while IBA1+ microglia are increased in sCJD staining, the intensity of TMEM119 staining is reduced compared to an age-matched non-demented control patient [97]. Deposits of misfolded PrPSc (sCJD) are also shown. Scale bar: 200 µm. (B) Besides microglia, astrocytes are also highly dysregulated in prion diseases such as sCJD [97,107], as displayed by the astrocyte markers GFAP and YKL-40 for an sCJD case and an age-matched control. Scale bar: 200 µm.](https://figures.cochat.ai/paper-figures/362a5ae09a934cbab0f3208b27c7341d/loss-of-homeostatic-microglia-signature-in-prion-diseases-figure-6.jpg)
![Figure 7 Disease-associated microglia profile differs between human sCJD and AD. Frontal cortex tissue of a sCJD patient and an age-matched AD patient show reactivity for the pan-microglia/macrophage marker IBA1, the microglial marker TMEM119, and the activation marker CD68 [97]. Deposits of misfolded proteins are shown for the respective antibodies against amyloid-β (AD) or PrPSc (sCJD). Note that the deposition pattern of misfolded PrPSc may vary considerably between CJD patients (see also Figure 6). In contrast to AD, microglia activation is more prominent and the microglial homeostasis marker is almost completely lost in sCJD [97]. Scale bar: 50 µm.](https://figures.cochat.ai/paper-figures/0844f8a2c05f4efb8ac1de84d350d243/loss-of-homeostatic-microglia-signature-in-prion-diseases-figure-7.jpg)
Verification
Claims the paper makes
22 Valid · 1 Not valid · 49 Not checked · 12 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several proinflammatory cytokines are upregulated in the brain during the prion disease course including TNF α, IL 1α, and C1qa [46,69,70,71,72,73].”
§ Loss of Homeostatic Microglia Signature in Prion Diseases > 1. Introduction > 1.1. Microglia Are Dysregulated and May Have a Dual Role in Prion Diseases
What the sources say
- Partly supportedcites [46] Carroll, 2018, Microglia Are Critical in Host Defense against Prion Disease, J. Virol. sourceExperimental — accuracy not yet measured
The Results (page unavailable) say several proinflammatory genes were increased in mouse brain during scrapie at 80 days post-infection, and Table 2 includes Il1a and Tnf among the genes assessed. Our copy does not identify C1qa as upregulated, and its evidence concerns a specified time point rather than the entire disease course. (LLM, conf=0.87)
- Not checked yetcites [69] Riemer, 2004, Gene expression profiling of scrapie-infected brain tissue, Biochem. Biophys. Res. Commun. source
- Not checked yetcites [70] Carroll, 2015, Prion infection of mouse brain reveals multiple new upregulated genes involved in neuroinflammation or signal transduction, J. Virol. source
- Partly supportedcites [71] Vincenti, 2015, Defining the Microglia Response during the Time Course of Chronic Neurodegeneration, J. Virol. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports increased Tnfa expression and a proinflammatory microglial response during prion disease. It names Il1b, not Il1a, among the increased cytokines, and the passages found do not establish increased C1qa expression. Thus this source supports the general point and TNF α example, but not the other two named examples. (LLM, conf=0.88)
- Partly supportedcites [72] Hwang, 2009, A systems approach to prion disease, Mol. Syst. Biol. sourceExperimental — accuracy not yet measured
The Results sections on PrPSc accumulation and microglial/astrocytic activation report increased C1qa/b mRNA and describe cytokine responses during prion infection. They do not identify TNF-α or IL-1α as upregulated, and they place C1qa in a complement pathway rather than identifying it as a cytokine. Page numbers are not available in our copy. (LLM, conf=0.86)
- Supportedcites [73] Hartmann, 2019, Complement 3(+)-astrocytes are highly abundant in prion diseases, but their abolishment led to an accelerated disease course and early dysregulation of microglia, Acta Neuropathol. Commun. source
The Introduction states that TNF-α, IL-1α, and C1qa are upregulated in the brain during the disease course in mouse prion disorders. The Discussion reiterates their upregulation in mouse models of prion disease; the claim is supported for that setting. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“while another stimulator of inflammation, the bacterial lipopolysaccharide (LPS), could not further stimulate their PrPSc-degrading function during disease progression [81].”
§ Loss of Homeostatic Microglia Signature in Prion Diseases > 1. Introduction > 1.1. Microglia Are Dysregulated and May Have a Dual Role in Prion Diseases
What the sources say
- Supportedcites [81] Hughes, 2010, Microglia in the degenerating brain are capable of phagocytosis of beads and of apoptotic cells, but do not efficiently remove PrPSc, even upon LPS stimulation, Glia source
The Conclusion states that secondary LPS challenge in ME7 prion-diseased animals, whether systemic or intracerebral, did not stimulate more efficient PrPSc clearance despite increased inflammation. The Results section likewise reports no significant PrPSc clearance near the intracerebral LPS injection site. (LLM, conf=0.94)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“First, microglia morphology is changed from the ramified presentation typical in homeostasis to a bushy/reactive or even amoeboid morphology in a region-dependent manner (Figure 3A,B) [45,46,47].”
§ Loss of Homeostatic Microglia Signature in Prion Diseases > 1. Introduction > 1.1. Microglia Are Dysregulated and May Have a Dual Role in Prion Diseases
What the sources say
- Partly supportedcites [45] Fransen, 2013, Regulation of microglial proliferation during chronic neurodegeneration, J. Neurosci. sourceExperimental — accuracy not yet measured
The section “The inhibition of microglial mitosis alters the inflammatory activation state” (page unavailable) reports larger microglial cell bodies and thicker processes in prion-diseased mice after AraC treatment. It does not establish a ramified-to-bushy or amoeboid change in untreated terminal disease. The “Time course of microglial proliferation” section reports regional differences in cell numbers, not morphology. (LLM, conf=0.78)
- Partly supportedcites [46] Carroll, 2018, Microglia Are Critical in Host Defense against Prion Disease, J. Virol. sourceExperimental — accuracy not yet measured
The Introduction and Discussion report microglial activation during prion disease, and the Discussion notes regional influences on microglial subpopulations. However, our copy does not describe a change from ramified to bushy or amoeboid morphology at terminal disease, or establish that such a change varies by region (searched: ramified, bushy, amoeboid, morphology). (LLM, conf=0.78)
- Partly supportedcites [47] Muth, 2017, Activation of microglia by retroviral infection correlates with transient clearance of prions from the brain but does not change incubation time, Brain Pathol. sourceExperimental — accuracy not yet measured
The Results section (‘Microglia homeostasis is severely disturbed in clinical prion disease’; page unavailable) reports highly activated microglia and region-dependent loss of the homeostatic marker P2ry12 in clinically prion-diseased mice. It does not describe a transition from ramified to bushy or amoeboid morphology, so the specific morphological claim is unsupported by this paper. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Moreover, microglia are directly activated by PrPSc in vitro [33,59]; however, such causalities are difficult to prove in vivo.”
§ Loss of Homeostatic Microglia Signature in Prion Diseases > 1. Introduction > 1.1. Microglia Are Dysregulated and May Have a Dual Role in Prion Diseases
What the sources say
- Not checked yetcites [33] Giese, 1998, Role of microglia in neuronal cell death in prion disease, Brain Pathol. source
- Supportedcites [59] Srivastava, 2018, Inflammatory response of microglia to prions is controlled by sialylation of PrP(Sc), Sci. Rep. source
The Results section on primary microglia reports that purified PrPSc significantly increased inflammatory markers and concludes that it can directly trigger an inflammatory response. The Methods section describes the in vitro exposure of cultured primary microglia and BV2 cells to purified PrPSc. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“The same outcome was recently published after region-specific bulk transcriptomic analyses of brains infected with two different prion strains [74]. Although these strains target different cell populations in the brain, the regional glia response was comparable.”
§ Loss of Homeostatic Microglia Signature in Prion Diseases > 1. Introduction > 1.1. Microglia Are Dysregulated and May Have a Dual Role in Prion Diseases
What the sources say
- Supportedcites [74] Makarava, 2020, Region-specific glial homeostatic signature in prion diseases is replaced by a uniform neuroinflammation signature, common for brain regions and prion strains with different cell tropism, Neurobiol. Dis. source
The Introduction describes gene-expression analysis of four mouse brain regions infected with the astrocyte-associated 22L or neuron-associated ME7 strain, using a NanoString neuroinflammation panel. The Discussion reports the same neuroinflammation signature for both strains across the regions, although its timing and degree of activation differed. The analysis used a targeted panel, not whole-transcriptome sequencing. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
37 more claims · 9 with their cited sources checked
Create a free account to see all 84 claims and to verify the 66 references still open.
- It may state two separate claims as one. 32
- Probably not a substantial claim. 17
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 1×
“Activated microglia represent a common feature of neurodegenerative diseases [54,66,67].”
BackgroundResting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827 · cited 2×
“As mention above, microglia in the healthy brain display a homeostatic morphology characterized by a small c ll body and l ng branching processes which are constantly surveying their enviro m nt [61].”
BackgroundA Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · cited 2×
“and others have identified a disease-specific microglia signature that is commonly dysregulated in brain diseases including AD [55,101].”
BackgroundFate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175
Novel Proteinaceous Infectious Particles Cause Scrapie
Prusiner, S. B. (1982) · Science · doi:10.1126/science.6801762 · Cited by 5,118 · cited 2×
“formation and disease progression [18] (Figure 1A).”
BackgroundSynaptic Pruning by Microglia Is Necessary for Normal Brain Development
Paolicelli, R. C., Bolasco, G., Pagani, F., Maggi, L., Scianni, M., Panzanelli, P., Giustetto, M., Ferreira, T. A., Guiducci, E., Dumas, L., et al. (2011) · Science · doi:10.1126/science.1202529 · Cited by 4,244 · cited 2×
“The targeting of unwan d ele e ts for remov involves complement receptors and adaptor proteins, among other signals [62,64].”
BackgroundKettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547 · cited 1×
“The latter enables microglia to increase their phagocytic capacity to remove unwanted structures and to release proinflammatory mediators including cytokines and chemokines [65].”
BackgroundThe Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313 · cited 2×
“The targeting of unwan d ele e ts for remov involves complement receptors and adaptor proteins, among other signals [62,64].”
Background
Cited by
Microglia Signatures: A Cause or Consequence of Microglia-Related Brain Disorders?
Mirarchi, A., Albi, E., & Arcuri, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010951 · Cited by 54
“The identified molecular pathways could represent potential therapeutic targets to modulate microglia activity and slow disease progression [123,124].”
BackgroundSynapse vulnerability and resilience across the clinical spectrum of dementias
Taddei, R. N., & Duff, K. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01094-7 · Cited by 27
“Published online: 22 May 2025”
Hay, A. J. D., Popichak, K. A., Mumford, G., Shirley, P. M., Bian, J., Wolfrath, L., Lei, S., Eggers, M., Nicholson, E. M., Tjalkens, R. B., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1012582 · Cited by 13
“Microglia scavenge and phagocytose PrP Sc , which results in a phenotypic change from scavenging and ramified to activated and amoeboid, often denoted as a shift from M2 to M1, or homeostatic microglia to disease-associated microglia (DAM) [6,38,40,41,50,54].”
Adipose-derived mesenchymal stromal cells decrease prion-induced glial inflammation in vitro
Hay, A. J. D., Murphy, T. J., Popichak, K. A., Zabel, M. D., & Moreno, J. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-26628-7 · Cited by 13
Pehar, M., Hewitt, M., Wagner, A., Sandhu, J. K., Khalili, A., Wang, X., Cho, J., Sim, V. L., & Kulka, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-75982-1 · Cited by 8
“Although many studies have indicated that microglia are involved in prion disease 69–71 , very few studies have investigated PrP C expression in human microglia; we are one of the first to directly show PrP C protein expression in human-derived microglia.”
Background
Metadata
- Authors
- Wang, Y., Hartmann, K., Thies, E., Mohammadi, B., Altmeppen, H., Sepulveda-Falla, D., Glatzel, M., & Krasemann, S.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany
- Corresponding author
- Krasemann, Susanne
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2022-09-21
- Volume
- 11
- Issue
- 19
- Pages
- 2948
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC9563810
- OpenAlex
- W4296991042
- Cited by
- 12
- References
- 122
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 7 · 2022: 1
- FWCI
- 0.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- China Scholarship Council (202108410135)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- prion disease, microglia, microglial homeostasis, microglial activation, cellular prion protein, PrPSc, neurodegeneration, astrocytes, microglial markers, neuroinflammation
- MeSH terms
- Prion Proteins, Animals, Homeostasis, Humans, Prions, Prion Diseases, Microglia, Neurodegenerative Diseases, Protein Isoforms, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Loss of Homeostatic Microglia Signature in Prion Diseases. https://app.cochat.ai/papers/10.3390/cells11192948
- The paper
- Wang, Y., Hartmann, K., Thies, E., Mohammadi, B., Altmeppen, H., Sepulveda-Falla, D., Glatzel, M., & Krasemann, S. (2022). Loss of Homeostatic Microglia Signature in Prion Diseases. Cells. https://doi.org/10.3390/cells11192948
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.